A Cohort Study to Compare the Hospitalization Between Naive Sacubitril/Valsartan and Naive ACEi/ARBs Heart Failure Patients With Reduced Ejection Fraction Using Secondary US Electronic Health Records Data

Inclusion Criteria: Sacubitril/valsartan incident cohort Included patients * Prescribed sacubitril/valsartan within the identification period (01-July-2015 to 31-Mar-2019), that had non-missing gender and year of birth data. * With at least one ICD-9-CM or ICD-10-CM code for diagnosis of HF within one-year prior to date of first prescription of sacubitril/valsartan (index date), and are treated as part of the integrated delivery network. * With first month active 365 days prior to index and last date active was greater than or equal to (≥) index, and the month of provider source data was greater than the final date of patient follow-up. * That were ≥18 years old at index date. * With a valid LVEF value ≤40%, prior to index (index date included). Angiotensin-converting enzyme inhibitors (ACEi) and Angiotensin II receptor antagonist (ARB) incident cohort Included patient: * Prescribed ACEi or ARBs within the identification period (01-Jul-2015 to 31-Mar-2019), that had non-missing gender and year of birth data. * With at least one ICD-9-CM or ICD-10-CM code for diagnosis of HF within one-year prior to date of first prescription of ACEi or ARB (index date), and were treated as part of the integrated delivery network. * With first month active 365 days prior to index and last date active was ≥ index, and the month of provider source data is greater than the final date of patient follow-up. * That were ≥ 18 years old at index date. * With a valid LVEF value ≤ 40%, prior to index (index date included). Exclusion Criteria: Sacubitril/valsartan incident cohort Excluded patients for the primary objective and secondary objective 2 to 6: * Patients who were prescribed sacubitril/valsartan within one-year prior to index date. * Patients who were prescribed ACEi or ARBs, within one-year prior to index date (index date included). Exclude patients for secondary objective 1: * Patients who were prescribed sacubitril/valsartan prior to index date. * Patients who were prescribed ACEi or ARBs prior to index date (index date included). Angiotensin-converting enzyme inhibitors (ACEi) and Angiotensin II receptor antagonist (ARB) incident cohort Exclude patients for the primary objective and secondary objective 2 to 6: * Patients who were prescribed ACEi or ARBs within one-year prior to index date. * Patients who were prescribed sacubitril/valsartan within one-year prior to index date (index date included). * Which had a valid sacubitril/valsartan prescription that enables inclusion in the sacubitril/valsartan cohort. * Exclude patients for secondary objective 1: * Patients who were prescribed ACEi or ARBs prior to index date. * Patients who were prescribed sacubitril/valsartan prior to index date (index date included). * Which had a valid sacubitril/valsartan prescription that enables inclusion in the sacubitril/valsartan cohort